Myriad Genetics announces the launch of the Precise MRD test with a select number of oncology practices for patients with breast cancer....
SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of the Precise MRD… [+5366 chars]









